Spots Global Cancer Trial Database for Safety and Efficacy of Immune Therapy for Condyloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of Immune Therapy for Condyloma
Official Title: Safety and Efficacy of Immune Therapy for Condyloma
Study ID: NCT03158480
Conditions
Interventions
Study Description
Brief Summary: Cytokine-induced killer (CIK) cells will be co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to Condylomata Acuminata patients using interferon, whose recurrence rate and total cost will be compared to Condylomata Acuminata patients only use interferon.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shenzhen Second Hospital, Shenzhen, Guangdong, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
